Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 256

The DOI matches its Crossref record; 78 of the 78 references it cites were found in a registry or an index.

The MOGE(S) Classification for a Phenotype–Genotype Nomenclature of Cardiomyopathy

Open access
Arbustini, Eloisa, Narula, Navneet, Dec, G. William, Reddy, K. Srinath, Greenberg, Barry, Kushwaha, Sudhir, Marwick, Thomas, Pinney, Sean, Bellazzi, Riccardo, Favalli, Valentina, Kramer, Christopher, Roberts, Robert, Zoghbi, William A., Bonow, Robert, Tavazzi, Luigi, Fuster, Valentin, Narula, Jagat·2013·Journal of the American College of Cardiology

Abstract

In 1956, Blankerhorn and Gall (1) proposed the term myocarditis for inflammatory heart muscle disease, and myocardiosis for other heart muscle diseases. A year thereafter, Brigden (2) defined cardiomyopathies as uncommon, non-coronary heart muscle diseases. Subsequently, Goodwin and Oakley (3) defined cardiomyopathies as myocardial diseases of unknown origin, and proposed categorization of the disorders as dilated (DCM), hypertrophic (HCM), and restrictive (or obliterative) (RCM) cardiomyopathies. In 1980, the World Health Organization (WHO) and International Society and Federation of Cardiology (ISFC) established the definition of cardiomyopathies as myocardial diseases of unknown etiology, reflecting the general lack of information about the mechanism(s) of disease (4). Although WHO-ISFC retained the 3 morphological types of cardiomyopathies proposed by Goodwin and Oakley, it also introduced the term specific heart muscle disease, where the cause of myocardial dysfunction was known. The WHO-ISFC classification subsequently expanded the definition of cardiomyopathies by adding the functional component and defined cardiomyopathy as the diseases of myocardium associated with myocardial dysfunction. Two additional classes, arrhythmogenic right ventricular cardiomyopathy (ARVC) and unclassified cardiomyopathy, were introduced during the revision, and the category of the specific heart muscle disease was excluded (5). The ISFC changed its name to the World Heart Federation (WHF) in 1998 (6), and did not indulge in further revision of the recommendations for either diagnosis or management of cardiomyopathies. A substantial increase in the knowledge of the genetic basis of cardiomyopathy has occurred, and noninvasive phenotypic characterization has become significantly more sophisticated. Therefore, the American Heart Association (AHA) (7) and the European Society of Cardiology (ESC) (8) in the last decade have proposed revisions to the classification of cardiomyopathic disorders. Whereas both systems have substantial similarities and have made important recommendations, the former has described cardiomyopathies starting from the genetic basis of the etiology followed by the phenotypic description of myocardial involvement. Conversely, the ESC has retained the description in original morphofunctional categories with further subclassification into genetic (familial) and nongenetic (nonfamilial) groups. Both classifications continue to exclude specific heart muscle disease (resulting from coronary, hypertensive, valvular, and congenital heart disease) from consideration as a cardiomyopathic disorder. There is no denying the fact that most cardiomyopathies are genetic diseases, which in the real life are brought to clinical attention (and diagnosed and managed) based on a phenotypic diagnosis. More than 60 disease genes have been identified to date (9); genes such as MYBPC3 may be associated with different phenotypes (HCM, RCM, DCM), and genes such as DYS may cause a unique phenotype (DCM only). The penetrance of the genetic mutation is variable, and phenotypic manifestations are often age dependent. Most genetic cardiomyopathies are inherited as autosomal dominant traits, with a minority of families demonstrating autosomal recessive, X-linked recessive or dominant (rare), and matrilineal inheritance. Cascade family screening and follow-up have become mandatory (10). It has become necessary for a more descriptive nosology to be developed that may encompass either all attributes of the individual patient cardiomyopathy or allow a common platform for collaborative research efforts. A number of experts, including clinical cardiologists, heart failure–transplantation physicians, geneticists, and cardiovascular imagers, have proposed a systematic nomenclature endorsed by the WHF Scientific Committee. The proposed classification is a descriptive presentation of the cardiomyopathic process, which is flexibly modifiable and expandable. This nosology is inspired from the TNM staging of tumors and is being simultaneously published by the Journal of the American College of Cardiology and the official journal of the WHF, Global Heart.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jacc.2013.08.1644

Cites

78 of 78 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 78 references

Research works printed but not linked: 16

  1. Blankerhorn, 1956, Myocarditis and myocardosis: a clinicopathologic appraisal, Circulation, 13, 217, 10.1161/01.CIR.13.2.217 · doi:10.1161/01.cir.13.2.217
  2. Snellen, 1980, Birth and growth of the European Society of Cardiology, Eur Heart J, 1, 5, 10.1093/oxfordjournals.eurheartj.a061095 · doi:10.1093/oxfordjournals.eurheartj.a061095
  3. Diegoli, 2011, Diagnostic work-up and risk stratification in X-linked dilated cardiomyopathies caused by dystrophin defects, J Am Coll Cardiol, 58, 925, 10.1016/j.jacc.2011.01.072 · doi:10.1016/j.jacc.2011.01.072
  4. von Nandelstadh, 2011, Analysis of myotilin turnover provides mechanistic insight into the role of myotilinopathy-causing mutations, Biochem J, 436, 113, 10.1042/BJ20101672 · doi:10.1042/bj20101672
  5. Piccolo, 1994, Dilated cardiomyopathy requiring cardiac transplantation as initial manifestation of Xp21 Becker type muscular dystrophy, Neuromuscul Disord, 4, 143, 10.1016/0960-8966(94)90006-X · doi:10.1016/0960-8966(94)90006-x
  6. Van Der Starre, 2013, Late profound muscle weakness following heart transplantation due to Danon disease, Muscle Nerve, 47, 135, 10.1002/mus.23517 · doi:10.1002/mus.23517
  7. Katzin, 2008, Pompe disease: a review of the current diagnosis and treatment recommendations in the era of enzyme replacement therapy, J Clin Neuromuscul Dis, 9, 421, 10.1097/CND.0b013e318176dbe4 · doi:10.1097/cnd.0b013e318176dbe4
  8. Hadley, 1971, Cardiac lesions in a patient with familial neurovisceral lipidosis (generalized gangliosidosis), Am J Clin Path, 55, 237, 10.1093/ajcp/55.2.237 · doi:10.1093/ajcp/55.2.237
  9. Benson, 1976, GM1-generalized gangliosidosis variant with cardiomegaly, Postgrad Med J, 52, 159, 10.1136/pgmj.52.605.159 · doi:10.1136/pgmj.52.605.159
  10. Venugopalan, 2002, Cardiac involvement in infantile Sandhoff disease, J Paediatr Child Health, 38, 98, 10.1046/j.1440-1754.2002.00765.x · doi:10.1046/j.1440-1754.2002.00765.x
  11. Krivit, 1972, Generalized accumulation of neutral glycosphingolipids with GM2 ganglioside accumulation in the brain. Sandhoff's disease (variant of Tay-Sachs disease), Am J Med, 52, 763, 10.1016/0002-9343(72)90082-4 · doi:10.1016/0002-9343(72)90082-4
  12. Arbustini, 2002, Electron and immuno-electron microscopy of abdominal fat identifies and characterizes amyloid fibrils in suspected cardiac amyloidosis, Amyloid, 9, 108, 10.3109/13506120208995243 · doi:10.3109/13506120208995243
  13. Millat, 2011, Clinical and mutational spectrum in a cohort of 105 unrelated patients with dilated cardiomyopathy, Eur J Med Genet, 54, e570, 10.1016/j.ejmg.2011.07.005 · doi:10.1016/j.ejmg.2011.07.005
  14. Olsen, 2003, Clear relationship between ETF/ETFDH genotype and phenotype in patients with multiple acyl-CoA dehydrogenation deficiency, Hum Mutat, 22, 12, 10.1002/humu.10226 · doi:10.1002/humu.10226
  15. Lundemose, 1997, Fatty acid oxidation disorders as primary cause of sudden and unexpected death in infants and young children: an investigation performed on cultured fibroblasts from 79 children who died aged between 0-4 years, Molec Path, 50, 212, 10.1136/mp.50.4.212 · doi:10.1136/mp.50.4.212
  16. Yamak, 2007, Exclusive cardiac dysfunction in familial primary carnitine deficiency cases: a genotype-phenotype correlation, Clin Genet, 72, 59, 10.1111/j.1399-0004.2007.00814.x · doi:10.1111/j.1399-0004.2007.00814.x

Cited by

See all 256

Metadata

Authors
Arbustini, E., Narula, N., Dec, G. W., Reddy, K. S., Greenberg, B., Kushwaha, S., Marwick, T., Pinney, S., Bellazzi, R., Favalli, V., Kramer, C., Roberts, R., Zoghbi, W. A., Bonow, R., Tavazzi, L., Fuster, V., & Narula, J.
Venue
Journal of the American College of Cardiology
Publisher
Elsevier BV
Published
2013-12
Volume
62
Issue
22
Pages
2046-2072
ISSN
0735-1097 (ISSN-L)
OpenAlex
W1519683225
Cited by
256
References
78
FWCI
11.23
Type
journal article
Language
en
Update notices
erratum (2014-01-21)
Open access
bronze
Licence
Funders
  • European Union INHERITANCE (n°241924)
  • Italian Ministry of Health “Diagnosis and Treatment of Hypertrophic Cardiomyopathies” (n°RF-PSM-2008-1145809)
  • Novartis
  • Siemens Healthcare
  • GE Healthcare and Phillips

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The MOGE(S) Classification for a Phenotype–Genotype Nomenclature of Cardiomyopathy. https://app.cochat.ai/papers/10.1016/j.jacc.2013.08.1644
The paper
Arbustini, E., Narula, N., Dec, G. W., Reddy, K. S., Greenberg, B., Kushwaha, S., Marwick, T., Pinney, S., Bellazzi, R., Favalli, V., Kramer, C., Roberts, R., Zoghbi, W. A., Bonow, R., Tavazzi, L., Fuster, V., & Narula, J. (2013). The MOGE(S) Classification for a Phenotype–Genotype Nomenclature of Cardiomyopathy. Journal of the American College of Cardiology. https://doi.org/10.1016/j.jacc.2013.08.1644

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.